Institutional subscriptions are print only and do not include online access. For online access, please contact Ovid.
Member pricing is for AAN members only. To become an AAN member, visit AAN.com/membership or call 800-361-0633 (outside North America call 301-223-2300).
Country:
*Institutional subscriptions are Print only and do not include online access. For online access, please contact Ovid.
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and considers contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy.
An individual subscription includes 10 issues with full-text online access to all current and back issues. Visit the journal online at anti-cancerdrugs.com
ISBN/ISSN
1473-5741
Product Format
Online Journal Only
Publication Frequency
Published 10 times per year
Paul Dent Ph.D
Professor Paul Dent, VCU Massey Cancer Center, Richmond VA, USA
--Research Articles - Original studies on basic preclinical or clinical research. --Case Reports --Review Articles --Letters to the Editor --Fast publication time --Provides new developments and breakthrough research
Your cart cannot contain products from multiple regions.
If you click continue, items in the cart from the previous
region will be removed. To keep items from the previous
region in your cart, click cancel.
This item is not related to current region.
AAOS members get an exclusive discount. Please click continue to log in as an AAOS member.
AHA members get an exclusive discount. Please click continue to log in as an AHA member.